Journal
JOURNAL OF NEUROLOGY
Volume 267, Issue 8, Pages 2296-2300Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-020-09830-3
Keywords
Genetics; Parkinson's disease; Clinical neurology; PET; Movement disorders
Categories
Funding
- Independent Research Fund Denmark
Ask authors/readers for more resources
Neuroinflammation (microglial activation) and subclinical nigrostriatal dysfunction have been reported in subjects at risk of Parkinsonism. Eight non-manifesting carriers (NMCs) of LRRK2 G2019S mutation had C-11-PK11195 and F-18-DOPA PET to assess microglial activation and striatal dopamine system integrity, respectively. Comparisons were made with healthy controls. Five LRRK2-NMCs had subclinical reductions of putaminal F-18-DOPA uptake. Three of them had significantly raised nigral C-11-PK11195 binding bilaterally. These findings indicate that nigrostriatal dysfunction and neuroinflammation occur in LRRK2-NMCs. Studies in larger cohorts with appropriate follow-up are needed to elucidate the significance of neuroinflammation in the premotor phase of LRRK2-PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available